Brenig Therapeutics Funding: $65M Raised, Series A (2024)
Brenig Therapeutics is based in Amsterdam, Netherlands. It has raised $65M in total funding. Latest round: Series A.
Brenig Therapeutics funding overview
Brenig Therapeutics is based in Amsterdam, Netherlands. Brenig Therapeutics has raised $65M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in July 2024. The round record for Brenig Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include New Enterprise Associates, OrbiMed, Torrey Pines Investments, BioGeneration Ventures. 4 distinct backers are named across the disclosed rounds.
Brenig Therapeutics at a glance
Total raised
$65M
Latest round
Series A
Latest round date
July 2024
Headquarters
Amsterdam, Netherlands
Notable investors
New Enterprise Associates, OrbiMed, Torrey Pines Investments, BioGeneration Ventures
Frequently asked about Brenig Therapeutics funding
How much has Brenig Therapeutics raised?
Brenig Therapeutics has raised $65M in total disclosed funding across the rounds on record.
Who has invested in Brenig Therapeutics?
New Enterprise Associates, OrbiMed, Torrey Pines Investments, BioGeneration Ventures are named among the investors backing Brenig Therapeutics.
What was the latest Brenig Therapeutics funding round?
The most recent disclosed round is a Series A, announced in July 2024.
Where is Brenig Therapeutics based?
Brenig Therapeutics is based in Amsterdam, Netherlands.
When did Brenig Therapeutics last raise?
The last disclosed Brenig Therapeutics round closed in July 2024 at Series A.
Round data for Brenig Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Amsterdam and backer lists below.
